Primary Sclerosing Cholangitis

North America contributes the largest share of the Primary Sclerosing Cholangitis Market

by

The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 3,604.7 Mn in 2022 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:-

Primary sclerosing cholangitis (PSC) is a chronic, progressive liver disease characterized by scarring and inflammation of bile ducts inside and outside of the liver. As bile ducts become blocked and narrowed, bile cannot flow normally, resulting in damage to liver cells. The disease has no cure and often leads to liver cirrhosis or liver cancer. Treatments aim to relieve symptoms and slow disease progression.

Market key trends:-

Growing R&D investment in developing novel drug treatments is fueling market growth. While ursodeoxycholic acid (UDCA) remains the standard treatment for PSC, its effectiveness is limited, necessitating alternative therapies. Several pharmaceutical companies are conducting clinical trials evaluating molecules targeting specific pathways involved in PSC pathogenesis. For instance, Phase 3 trials are evaluating the effectiveness of obeticholic acid from Intercept Pharmaceuticals for PSC. In another example, a Phase 2 trial is assessing the safety and efficacy of cenicriviroc, an immunomodulator from Allergan, for treating PSC. Pipeline drugs inhibiting fibrogenic pathways and modulating bile acid metabolism also show promise. The emergence of targeted therapies may offer improved management of PSC symptoms and slow disease progression if clinical success is achieved. Their approval would capture significant market share in the coming years.

Segment Analysis:-

The primary sclerosing cholangitis market is dominated by the idiopathic segment, which holds over 65% share of the total market. This segment is dominant as in majority of primary sclerosing cholangitis cases, the exact cause remains unknown. Other notable segments include drug-induced primary sclerosing cholangitis and infection-related primary sclerosing cholangitis. However, these segments are expected to witness comparatively lower growth during the forecast period.

Key Takeaways:-

The Global Primary Sclerosing Cholangitis Market Size is expected to witness high growth, exhibiting CAGR of 4.6% over the forecast period, due to increasing research funding for developing novel therapies.

North America dominates the global primary sclerosing cholangitis market and is estimated to continue its dominance during the forecast period. This is attributed to growing prevalence of inflammatory bowel disease in the region.

Europe is the second largest as well as fastest growing market for primary sclerosing cholangitis. Increasing awareness initiatives by patient advocacy groups support the market growth in the region.

Key players operating in the primary sclerosing cholangitis market are Allergan Plc, Conatus Pharmaceuticals, Dr. Falk Pharma GmbH, Intercept Pharmaceuticals, Inc., Mirum Pharmaceuticals. These players are focusing on developing advanced therapeutics to expand their product offerings.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it